



Source: Noema Pharma

March 07, 2023 02:00 ET

Noema Pharma Raises CHF 103 Million (USD 112 Million) in Series B Financing Round Led by Forbion and Jeito Capital

- Oversubscribed financing to support continued development of its diversified pipeline focused on central nervous system disorders
- Nanna Lüneborg, General Partner at Forbion and Rachel Mears, Partner at Jeito Capital to join Board of Directors
- Multiple Phase 2b trials in orphan and mainstream CNS indications continue to advance

BASEL, Switzerland, March 07, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced that it has successfully closed an oversubscribed Series B financing round, raising CHF 103 million (approx. USD 112 million) from new and existing investors. The round was co-led by leading European healthcare focused investment firms Forbion and Jeito Capital. UPMC Enterprises and an additional new investor joined existing investors Sofinnova Partners, Polaris Partners, Gilde Healthcare and Invus to complete the round. Following the close of the Series B financing, Nanna Lüneborg from Forbion and Rachel Mears from Jeito Capital will join the Board of Directors of Noema Pharma.

The proceeds of the Series B financing will be used to advance Noema Pharma's clinical-stage assets including its lead compound basimglurant (NOE-101), an mGluR5 inhibitor which is being evaluated in Phase 2b clinical trials for severe pain in Trigeminal Neuralgia (TN) and seizures in Tuberous Sclerosis Complex (TSC). The Company is also developing gemlapodect (NOE-105), a PDE10a inhibitor being evaluated in Phase 2b clinical trials for Tourette Syndrome and Childhood Onset Fluency Disorder (COFD) or Stuttering; and NOE-115, a Phase 2 ready triple reuptake inhibitor for Atypical Depression and Binge Eating Disorder.

*"We are excited to announce the successful completion of this oversubscribed Series B financing round and very pleased to have a world-class group of investors supporting our vision of bringing much-needed treatments to those living with debilitating central nervous system disorders," said **Luigi Costa, Chief Executive Officer of Noema Pharma**. "We welcome our new investors who bring extensive expertise and knowledge of drug development and company building and add further strength to our robust investor base. This financing comes at a key time for Noema Pharma as we look forward to extensive news flow over the next 24 months."*

*"We have been following Noema since inception and have been impressed by the quality and progress of Noema Pharma's clinical pipeline. We believe this is the right time to invest as the Company has started to generate very encouraging clinical data in indications of high unmet need and particularly with its lead asset basimglurant. We are therefore delighted to back Noema from our second Growth Opportunities Fund which focuses on investments in late-stage European drug development companies. We believe Noema to be at the forefront of a significant new wave of innovation in the field of central nervous system disorders which impact millions globally" explained **Nanna Lüneborg, General Partner at Forbion**.*

*"One of the pillars of our investment strategy is to deploy capital in truly differentiated and innovative therapies with high unmet medical need," said **Rachel Mears, Partner at Jeito Capital**. "The research and clinical work being undertaken by Noema Pharma fit these criteria exactly. The dedication of the Noema team and the quality of their work is clear to see and positions the company as the upcoming global leader in its field."*

*"As co-founders and initial investors of Noema Pharma, we are incredibly proud of what the company has accomplished since its inception," said **Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners**. "Raising an oversubscribed funding round of this magnitude is a significant achievement, that further reinforces our conviction that Noema can make a meaningful difference in the lives of patients suffering from debilitating CNS disorders."*

The Series B financing follows a CHF 54 million (approx. USD 60 million) Series A financing concluded in December 2020, led by Sofinnova Partners and Polaris Partners. Noema Pharma was founded in 2019 with a seed investment from Sofinnova Partners and four clinical stage assets in-licensed from Roche.

About Noema Pharma

Noema Pharma (www.noemapharma.com) is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The Company has a well differentiated pipeline with four mid clinical-stage therapeutic product candidates in-licensed from Roche. Noema currently has 3 active Phase 2b clinical trials in highly undertreated CNS conditions: seizures in Tuberous Sclerosis Complex, severe pain in Trigeminal Neuralgia and Childhood Onset Fluency Disorder. The Company has completed a Phase 2a clinical trial in adult patients with Tourette Syndrome that is currently being extended with an adolescent cohort. The Company has also completed preclinical validation studies in Atypical Depression and Binge Eating Disorder. Noema Pharma was founded in 2019 by the leading venture capital firm Sofinnova Partners. Additional investors include Biomed Partners, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners, UPMC Enterprises, and an undisclosed investor.

Contacts

Noema Pharma

Michael Gutch, PhD
Chief Financial Officer
info@noemapharma.com

Investors

LifeSci Advisors – Guillaume van Renterghem
gvanrenterghem@lifesciadvisors.com
+41 (0) 76 735 01 31